| Svetlana Viktorovna Dueger, DPT | |
|
39 Hospital Center Cmns, Hilton Head Island, SC 29926-2837 | |
| (843) 689-2233 | |
| (843) 689-2234 |
| Full Name | Svetlana Viktorovna Dueger |
|---|---|
| Gender | Female |
| Speciality | Physical Therapist |
| Location | 39 Hospital Center Cmns, Hilton Head Island, South Carolina |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053172544 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225100000X | Physical Therapist | 12188 (South Carolina) | Primary |
| Provider Name | Beaufort Orthopaedic Sports And Spine Center Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1982765160 PECOS PAC ID: 1355301771 Enrollment ID: O20041012000064 |
News Archive
A new delivery system for bacteriophages-;viruses that selectively attack harmful bacteria-;could help give doctors a new way to battle lung infections that threaten older patients and people with cystic fibrosis.
Semafore Pharmaceuticals today reported encouraging data from a Phase I dose-escalation trial of SF1126 in patients with relapsed and refractory myeloma. SF1126 is a novel small molecule inhibitor of phosphoinositide-3-kinase (PI3K) and mammalian target of rapamycin (mTOR), two key members of the PI3K signaling pathway that is vital to several essential biological processes, such as cell proliferation and survival. PI3K is commonly altered in human cancers, making inhibition of the target attractive for cancer therapy.
Graduates of the Hebrew University's Biodesign program revealed a robotic intubation device that automatically identifies the lungs using an infrared source and navigates toward it.
Today, the U.S. Food and Drug Administration granted accelerated approval to Polivy (polatuzumab vedotin-piiq), in combination with the chemotherapy bendamustine and a rituximab product (a combination known as "BR"), to treat adult patients with diffuse large B-cell lymphoma (DLBCL) that has progressed or returned after at least two prior therapies.
They found that the anti-cancer drug imatinib mesylate — commercially known as Gleevec and produced by Novartis Pharmaceuticals — can target a gene critical to controlling the disease process. Previously, there had been no treatment and patients usually did not survive beyond three years of diagnosis. Now the treatment is undergoing clinical trials at Mayo Clinic.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Svetlana Viktorovna Dueger, DPT 39 Hospital Center Cmns, Hilton Head Island, SC 29926-2837 Ph: (843) 689-2233 | Svetlana Viktorovna Dueger, DPT 39 Hospital Center Cmns, Hilton Head Island, SC 29926-2837 Ph: (843) 689-2233 |
News Archive
A new delivery system for bacteriophages-;viruses that selectively attack harmful bacteria-;could help give doctors a new way to battle lung infections that threaten older patients and people with cystic fibrosis.
Semafore Pharmaceuticals today reported encouraging data from a Phase I dose-escalation trial of SF1126 in patients with relapsed and refractory myeloma. SF1126 is a novel small molecule inhibitor of phosphoinositide-3-kinase (PI3K) and mammalian target of rapamycin (mTOR), two key members of the PI3K signaling pathway that is vital to several essential biological processes, such as cell proliferation and survival. PI3K is commonly altered in human cancers, making inhibition of the target attractive for cancer therapy.
Graduates of the Hebrew University's Biodesign program revealed a robotic intubation device that automatically identifies the lungs using an infrared source and navigates toward it.
Today, the U.S. Food and Drug Administration granted accelerated approval to Polivy (polatuzumab vedotin-piiq), in combination with the chemotherapy bendamustine and a rituximab product (a combination known as "BR"), to treat adult patients with diffuse large B-cell lymphoma (DLBCL) that has progressed or returned after at least two prior therapies.
They found that the anti-cancer drug imatinib mesylate — commercially known as Gleevec and produced by Novartis Pharmaceuticals — can target a gene critical to controlling the disease process. Previously, there had been no treatment and patients usually did not survive beyond three years of diagnosis. Now the treatment is undergoing clinical trials at Mayo Clinic.
› Verified 1 days ago
Melissa Ashley Fober, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 8 Hospital Center Blvd Ste 250, Hilton Head Island, SC 29926 Phone: 843-671-7342 Fax: 843-671-7343 | |
Carl J Swearingen, PHYSICAL THERAPIST Physical Therapist Medicare: Medicare Enrolled Practice Location: 15 Moss Creek Vlg, Hilton Head Island, SC 29926 Phone: 843-836-7003 | |
Hope Life And Rehabilitation Center, Llc Physical Therapist Medicare: Medicare Enrolled Practice Location: 60 Main St Unit G, Hilton Head Island, SC 29926 Phone: 843-715-4146 Fax: 843-715-4673 | |
Katherine B Philpott, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 8 Hospital Center Blvd Ste 250, Hilton Head Island, SC 29926 Phone: 843-671-7342 Fax: 843-671-7343 | |
Scott Alan Stanas, Physical Therapist Medicare: Medicare Enrolled Practice Location: 39 Hospital Center Cmns, Hilton Head Island, SC 29926 Phone: 843-689-2233 Fax: 843-689-2234 | |
Danielle Elise Marris, PT Physical Therapist Medicare: Medicare Enrolled Practice Location: 39 Hospital Center Cmns, Hilton Head Island, SC 29926 Phone: 436-892-2338 Fax: 843-689-2234 |